Toggle Main Menu Toggle Search

Open Access padlockePrints

The relationship between hallucinations and FDG-PET in dementia with Lewy bodies

Lookup NU author(s): Dr Michael FirbankORCiD, Dr James LloydORCiD, Professor John O'Brien

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


Abstract

Visual hallucinations are common in dementia with Lewy bodies (DLB), although their etiology is unclear. This study aimed to investigate the relationship between severity and frequency of hallucinations and regional brain glucose metabolism. We performed brain FDG-PET scanning on 28 subjects with DLB (mean age 76). The neuropsychiatric index (NPI) was used to assess frequency and severity of hallucinations. We used the SPM package to investigate voxelwise correlations between NPI hallucination score (severity x frequency) and FDG uptake relative to the cerebellum. There was a bilateral medial occipital region where reduced FDG was associated with increased hallucination severity and frequency. We conclude that the reduced occipital metabolism frequently seen in DLB is associated with frequency and severity of visual hallucinations. Further studies are required to investigate whether this is the result of deficits in top-down or bottom-up visual processing pathways.


Publication metadata

Author(s): Firbank MJ, Lloyd J, O'Brien JT

Publication type: Article

Publication status: Published

Journal: Brain Imaging and Behavior

Year: 2016

Volume: 10

Issue: 3

Pages: 636-639

Print publication date: 01/09/2016

Online publication date: 04/08/2015

Acceptance date: 17/07/2015

Date deposited: 07/01/2016

ISSN (print): 1931-7557

ISSN (electronic): 1931-7565

Publisher: Springer New York LLC

URL: http://dx.doi.org/10.1007/s11682-015-9434-0

DOI: 10.1007/s11682-015-9434-0

PubMed id: 26239998


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
PB-PG-1207-13105National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme

Share